In a recent Phase 2 clinical trial for systemic lupus erythematosus (SLE), Orelabrutinib has made history as the inaugural BTK inhibitor to showcase substantial clinical efficacy. This groundbreaking development marks a significant milestone in the treatment of SLE, signifying a promising advancement in combating the disease. This advancement paves the way for further exploration and potential breakthroughs in SLE treatment.